They showed enhanced tumor cell-killing activity in a dose- and time-dependent manner while activating multiple signaling pathways, including granzyme–PRF1–PARP, Fas–FADD–caspase, and IFN-γ pathways. The gene discussed is PARP1; the disease is neoplasm.